RNAC
Cartesian Therapeutics, Inc.
$9.46
-0.21 (-2.17%)
At close · Jul 10
Market Cap
$277.95M
Shares
29,381,514
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.8M
-92.8%
FY2025
Net Income
-$130.3M
-68.3%
FY2025
Operating Margin
-5127.1%
-5014.3pp
FY2025
Diluted EPS
-$5.02
-11.8%
FY2025
Operating Cash Flow
-$73.94M
-212.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| $1.78M | $2.8M | $38.91M | $26M | $110.78M | $85.08M | $16.6M | $6.68M | $8.08M | |
| $62.82M | $58.03M | $45.11M | $71.84M | $72.38M | $68.74M | $54.51M | $42.74M | $29.7M | |
| $30.27M | $31.47M | $30.13M | $40.58M | $23.86M | $20.94M | $18.91M | $16.39M | $13.05M | |
| — | $0 | $798K | $6.43M | — | — | — | — | — | |
| $149.79M | $146.2M | $82.81M | $112.42M | $96.24M | $89.67M | $73.42M | $59.13M | $42.75M | |
| -$148.02M | -$143.41M | -$43.9M | -$86.42M | $14.54M | -$4.6M | -$56.82M | -$52.46M | -$34.67M | |
| — | -5127.1% | -112.81% | -332.32% | 13.12% | -5.4% | -342.36% | -785.61% | -428.92% | |
| — | — | $0 | $2.83M | $3.03M | $2.84M | $1.56M | $1.52M | $1.25M | |
| — | $6.58M | $7.39M | — | — | — | — | — | — | |
| -$12.95M | $3.91M | $606K | $691K | $330K | $15K | $89K | -$1.31M | $4000 | |
| — | -$139.5M | -$77.14M | -$238.71M | $34.77M | -$9.72M | — | — | — | |
| — | -$9.19M | $287K | -$19M | -$609K | $15.97M | — | — | — | |
| -$151.77M | -$130.3M | -$77.42M | -$219.71M | $35.38M | -$25.69M | -$68.88M | -$55.35M | -$36.21M | |
| — | -4658.63% | -198.97% | -844.91% | 31.94% | -30.19% | -414.99% | -828.97% | -447.98% | |
| — | -$130.3M | -$77.42M | -$257.26M | — | — | -$68.88M | -$55.35M | -$40.78M | |
| -$151.77M | -$130.26M | -$77.45M | -$219.75M | $35.39M | -$25.69M | -$68.92M | -$55.32M | -$35.74M | |
| USD/shares | — | -$5.02 | -$4.48 | -$49.80 | $7.20 | -$6.60 | — | — | — |
| USD/shares | — | -$5.02 | -$4.49 | -$49.80 | $3.00 | -$6.60 | — | — | — |
| shares | — | 25.97M | 17.28M | 5.17M | 4.83M | 3.81M | 3.37M | 1.52M | 349.8K |
| shares | — | 25.97M | 17.36M | 5.17M | 4.86M | 3.81M | 3.37M | 1.52M | 349.8K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Segment | $2,797,000 | $38,913,000 | — |
| Reporting Segments | — | — | $26,004,000 |
By Product & Service (USD)
| Component | 2019-12-31 |
|---|---|
| Grant | $100,000 |